Oral Drug Delivery Videos

  1. Charting The Waters Of Drug Delivery Innovation With Suttons Creek 7/11/2025

    In this episode of In Combination, the technical leadership team from device consultancy Suttons Creek joins host Tom von Gunden to discuss trends in the patient landscape driving innovation in drug delivery, including combination products and therapies. The conversation covers patient self-administration, emerging modalities, and key considerations in product development, regulatory pathways, and the supply chain.

  2. OSD Manufacturing For Pediatrics And Other Special Patient Populations 8/29/2024

    Watch to hear Steven Facer, Adare's Vice President of Business Development EU/ROW, discuss the challenges of pediatric oral solid dose manufacturing and how to overcome them.

  3. Setting The Strategic Direction For Advanced Therapy Products 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, underscores the importance of cascading business and regulatory strategies for advanced therapies and delivery products throughout the organization’s quality management systems. 

  4. Preferences And Challenges In Oral Drug Delivery 6/12/2026

    In this segment of the Drug Delivery Leader Live online event, Advanced Oral Delivery: Maximizing Molecules, Targets, And Adherence, Chief Editor Tom von Gunden asks panelist Eduardo Jule to provide a foundational overview of the current state of reliance on oral delivery. Jule points to patient preference for oral delivery while acknowledging challenges and limitations in the approach. 

  5. How High Drug Load Nanocrystalline Tablets Lower Pill Burden 3/12/2025

    We showcase the development of high drug load nanocrystal based tablets and prove that nanocrystals can match the pharmacokinetic performance of ASDs while reducing the overall pill burden.

  6. Leveraging Nanoparticles For High Drug Load Delivery With Nanoform's Christian Jones 7/28/2025

    In this episode of Supplier Horizons, host Tom von Gunden talks with Chief Commercial Officer Christian Jones of nanoparticle technology developer Nanoform about innovation in drug and biologics delivery. The discussion covers aspects of patient centricity such as aging populations, in-home self-administration, and personalized medicine. It also focuses on the use of nanotechnology in the delivery of high concentration formulations via oral and subcutaneous routes of administration. 

  7. Preparing For Combination Product Regulatory Inspections 4/11/2025

    In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 9 of The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press) with the book’s editor, Susan Neadle, and chapter co-author Kim Trautman.

  8. Increasing Spray Drying Throughput For Brick Dust Compounds

    ‘Brick dust’ compounds require additional steps if spray drying is to yield a commercially attractive process. Explore three enabling technologies designed to improve drug solubility in organic solvents for spray drying.

  9. What Types Of Products Are Assessed With A URRA? 12/11/2024

    What types of products in development may need to be assessed in accordance with the FDA’s URRA (Use-Related Risk Analysis) guidance? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, describes several common scenarios that illustrate when a URRA approach may or may not be needed.

  10. The Landscape For Advanced Therapies And Combination Products 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, traces key conditions driving and impacting the development of advanced therapies and combination products. These include the demand for precision medicines, the complexity of regulatory frameworks, and pressures on healthcare systems.